Taliban gunmen attack Pak air force base, 13 militants killed

Canadian researchers are developing a DNA vaccine for SARS-CoV-2, the coronavirus that causes COVID-19 and has currently infected nearly 5,00,000 people worldwide and crippled the global economy.

Entos Pharmaceuticals, a health-care biotechnology company headed by a University of Alberta researchers, develop new therapeutic compounds using the company's proprietary drug-delivery platform and has begun manufacturing vaccine candidates against the novel coronavirus.

"Given the urgency of the situation, we can have a lead candidate vaccine within two months. Once we have that it's a race to get it into clinical trials," said John Lewis, CEO of Entos and a Professor at the University of Alberta in Canada.

Lewis said in comparison to a traditional vaccine, DNA-based vaccines hold several advantages.

Nucleic acids are introduced directly into the patient's own cells, causing them to make pieces of the virus--tricking the immune system into mounting a response without the full virus actually being present, the researcher said.

According to the company, the approach is recognised as being easier to move into large-scale manufacturing, offers improved vaccine stability and works without needing an infectious agent.

In the current absence of a vaccine for COVID-19, several companies around the world are mounting efforts to begin similar work.

The first clinical trial using a DNA-based vaccine developed by Moderna Inc.in the US on March 13.

Their approach allows for antibodies to be made in the human trial volunteers against a specific protein on the surface of the coronavirus that lets the virus enter human cells.

The hope is that the antibodies will stop the interaction.

Though this approach is designed to be effective against COVID-19 specifically, Lewis said Entos is taking a different tack.

The company plans to use plasmid DNA to amplify the production of key coronavirus surface and structural proteins with each injection, with an eye to the bigger picture.

"Many of the structural proteins in the virus are pretty well conserved across all the coronaviruses, including SARS and MERS," said Lewis.

"We're hoping that if we express more of the structural proteins that are common to most coronaviruses, we can inhibit the current COVID-19, and also potentially protect against all coronaviruses both past and future," Lewis added.

To move the project forward quickly, the company is seeking financial support from both provincial and federal levels of government.

"We have the opportunity to save a lot of lives, and I think it's really upon us and governments to find solutions for that," Lewis said.

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Washington, Feb 23: U.S. president Donald Trump on Saturday said he was looking forward to being with his "great friends" in India next week as he retweeted a short video in which his face was superimposed on the hit movie-character Bahubali, showing the president as a great saviour bringing peace to his kingdom.

Trump will pay a state visit to India on February 24 and 25, accompanied by a high-level delegation including first lady Melania Trump, his daughter Ivanka, son-in-law Jared Kushner and a galaxy of top American officials.

"Look so forward to being with my great friends India!" Trump said in the tweet.

Along with the tweet, Trump retweeted an 81-second video by a Twitter account identified as "Sol" with the handle Solmemes1.

"To celebrate Trump's visit to India I wanted to make a video to show how in my warped mind it will go... USA and India united!" the handle Solmemes1 tweeted in the original post with the video.

Trump appears as a great saviour, in the short animated clip, riding on a chariot with Melania. A few stills later, Trump is seen riding a horse carrying on his shoulders his son Donald Jr and daughter Ivanka.

Later, he is welcomed by Narendra Modi in a village setting. Hundreds and thousands of people are seen welcoming Trump in the video.

"This week Trump will visit India and in celebration I have created a new meme for the occasion... You few, who are my patrons, get to see it first!" Sol told viewers on subscription content service Patreon on Saturday. A few hours later, Trump retweeted the video.

In the Twitter description, Sol describes herself as "award winning master memetician, professor of memology at University of GFY, my views are my own and not associated with real life."

The Trump-Bahubali video, which ends with "USA and India United", went viral after Trump retweeted it. In a few hours, it was seen by nearly 6 lakh people.

Sol in one of her previous posts, dated January 23, writes she was inspired by a video of Bahubali sent to her by a friend, which is the story of 'good defeating evil.'

This inspired Sol to create her first Bahubali-theme meme. The video, lasting 93 seconds, is titled "Jiyo Re Baahu Trump", in which the first lady is seen wearing a saree. "Jiyo Re Bahubali," is the theme song of the video.

"I just loved this video when I saw it! A friend sent it to me and he told me that it is the story of good defeating evil... it was so fitting I had to make it (meme)..." Sol wrote in her post.

Sol's posts show that she is an admirer of Trump. Sol's January 23 video was released at the peak of Trump's impeachment proceedings.

Trump is seen being greeted by an elephant, which bears the logo of the Republican Party.

Towards the end of the video, Trump is seen riding the elephant, and putting on fire the effigy of "Raavan" marked as "D" in a big circle representing the opposition Democratic Party.

An arrow is given by warrior Narendra Modi to the First Lady, who then passes it on to Trump, before he lights the effigy.